The challenge of sudden death in dialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 3, 2008, Pages 920-929

  Ritz, Eberhard ^a,c   Wanner, Christoph ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Nierenzentrum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT; SULFONYLUREA DERIVATIVE;

ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPERTENSION; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RENAL REPLACEMENT THERAPY; RISK FACTOR; SUDDEN DEATH;

CARDIOVASCULAR AGENTS; DEATH, SUDDEN, CARDIAC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERKALEMIA; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 44649181666     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04571007     Document Type: Conference Paper

References (85)

1. Wanner C, Krane V, Marz W, Olschewski M, Mann J, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005
2. Holmberg B, Brannstrom M, Bucht B, Crougneau V, Dimeny E, Ekspong A, Granroth B, Grontoft KC, Hadimeri H, Ingman B, Isaksson B, Johansson G, Lindberger K, Lundberg L, Mikaelsson L, Olausson E, Persson B, Welin D, Wikdahl AM, Stegmayer BG: Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scand J Urol Nephrol 39: 503-510, 2005
3. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M: Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110: 1557-1563, 2004
4. Myerburg RJ, Kessler KM, Castellanos A: Sudden cardiac death: Structure, function, and time-dependence of risk. Circulation 85: I2-I10, 1992
5. Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, Camm AJ, Cappato R, Cobbe SM, Di Mario C, Maron BJ, McKenna WJ, Pedersen AK, Ravens U, Schwartz FJ, Trusz-Gluza M, Vardas P, Wellens HJ, Zipes DP: Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 22: 1374-1450, 2001 [erratum appears in Eur Heart J 123: 257, 2002]
6. Huikuri HV, Castellanos A, Myerburg RJ: Sudden death due to cardiac arrhythmias. N Engl J Med 345: 1473-1482, 2001
7. Sans S, Kesteloot H, Kromhout D: The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 18: 1231-1248, 1997
8. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R: Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 336: 1276-1282, 1997
9. Thomas AC, Knapman PA, Krikler DM, Davies MJ: Community study of the causes of "natural" sudden death. BMJ 297: 1453-1456, 1988
10. Leach IH, Blundell JW, Rowley JM, Turner DR: Acute ischaemic lesions in death due to ischaemic heart disease: An autopsy study of 333 cases of out-of-hospital death. Eur Heart J 16: 1181-1185, 1995
11. Herzog CA: Cardiac arrest in dialysis patients: Approaches to alter an abysmal outcome. Kidney Int Suppl S197-S200, 2003
12. Ritz ES, Katz F, Wing AJ, Quellhorst E: Hypertension and cardiovascular risk factors in hemodialyzed diabetic patients. Hypertension 7:II118-II124, 1985
13. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001
14. Gussak I, Gussak HM: Sudden cardiac death in nephrology: Focus on acquired long QT syndrome. Nephrol Dial Transplant 22: 12-14, 2007
15. Takeda K, Harada A, Okuda S, Fujimi S, Oh Y, Hattori F, Motomura K, Hirakata H, Fujishima M: Sudden death in chronic dialysis patients. Nephrol Dial Transplant 12: 952-955, 1997
16. van Dijk PC, Zwinderman AH, Dekker FW, Schon S, Stel VS, Finne P, Jager KJ: Effect of general population mortality on the north-south mortality gradient in patients on replacement therapy in Europe. Kidney Int 71: 53-59, 2007
17. Yoshino M, Kuhlmann MK, Kotanko P, Greenwood RN, Pisoni RL, Port FK, Jager KJ, Homel P, Augustijn H, de Charro FT, Collart F, Erek E, Finne P, Garcia-Garcia G, Gronhagen-Riska C, Ioannidis GA, Ivis F, Leivestad T, Lookegaard H, Lopot F, Jin DC, Kramar R, Nakao T, Nandakumar M, Ramirez S, van der Sande FM, Schon S, Simpson K, Walker RG, Zaluska W, Levin NW: International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. J Am Soc Nephrol 17: 3510-3519, 2006
18. Rosenstock L, Olsen J: Firefighting and death from cardiovascular causes. N Engl J Med 356: 1261-1263, 2007
19. Kirchhof P, Breithardt G, Eckardt L: Primary prevention of sudden cardiac death. Heart 92: 1873-1878, 2006
20. Haider AW, Larson MG, Benjamin EJ, Levy D: Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 32: 1454-1459, 1998
21. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE: Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 11: 1277-1285, 1996
22. Diamond JA, Phillips RA: Hypertensive heart disease. Hypertens Res 28: 191-202, 2005
23. Chinali M, de Simone G, Matteucci MC, Picca S, Mastrostefano A, Anarat A, Caliskan S, Jeck N, Neuhaus TJ, Peco-Antic A, Peruzzi L, Testa S, Mehls O, Wuhl E, Schaefer F, ESCAPE Trial Group: Reduced systolic myocardial function in children with chronic renal insufficiency. J Am Soc Nephrol 18: 593-598, 2007
24. Esler M, Jennings G, Lambert G, Meredith I, Horne M, Eisenhofer G: Overflow of catecholamine neurotransmitters to the circulation: Source, fate, and functions. Physiol Rev 70: 963-985, 1990
25. Meredith IT, Broughton A, Jennings GL, Esler MD: Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 325: 618-624, 1991
26. Rump LC, Amann K, Orth S, Ritz E: Sympathetic overactivity in renal disease: A window to understand progression and cardiovascular complications of uraemia? Nephrol Dial Transplant 15: 1735-1738, 2000
27. Tornig J, Amann K, Ritz E, Nichols C, Zeier M, Mall G: Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: The effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 7: 667-675, 1996
28. Chen PS, Chou CC, Tan AY, Zhou S, Fishbein MC, Hwang C, Karagueuzian HS, Lin SF: The mechanisms of atrial fibrillation. J Cardiovasc Electrophysiol 17[Suppl 3]: S2-S7, 1996
29. Khan R, Sheppard R: Fibrosis in heart disease: Understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 118: 10-24, 2006
30. Amann K, Breitbach M, Ritz E, Mall G: Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 9: 1018-1022, 1999
31. Dikow R, Kihm LP, Zeier M, Kapitza J, Tornig J, Amann K, Tiefenbacher C, Ritz E: Increased infarct size in uremic rats: Reduced ischemia tolerance? J Am Soc Nephrol 15: 1530-1536, 2004
32. Bleyer AJ, Hartman J, Brannon PC, Reeves-Daniel A, Satko SG, Russell G: Characteristics of sudden death in hemodialysis patients. Kidney Int 69: 2268-2273, 2006
33. Karnik JA, Young BS, Lew NL, Herget M, Dubinsky C, Lazarus JM, Chertow GM: Cardiac arrest and sudden death in dialysis units. Kidney Int 60: 350-357, 2001
34. Bleyer AJ, Russell GB, Satko SG: Sudden and cardiac death rates in hemodialysis patients. Kidney Int 55: 1553-1559, 1999
35. Amann K, Tornig J, Kugel B, Gross ML, Tyralla K, El-Shakmak A, Szabo A, Ritz E: Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 63: 1296-1301, 2003
36. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G, Cholesterol and Recurrent Events Trial Investigators: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112: 2627-2633, 2003
37. Willich SN, Goldberg RJ, Maclure M, Perriello L, Muller JE: Increased onset of sudden cardiac death in the first three hours after awakening. Am J Cardiol 70: 65-68, 1992
38. Gami AS, Howard DE, Olson EJ, Somers VK: Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med 352: 1206-1214, 2005
39. Mehra R, Benjamin EJ, Shahar E, Gottlieb DJ, Nawabit R, Kirchner HL, Sahaderan J, Redline S, Sleep Heart Health Study: Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. Am J Respir Crit Care Med 173: 910-916, 2006
40. Kimmel PL, Miller G, Mendelson WB: Sleep apnea syndrome in chronic renal disease. Am J Med 86: 308-314, 1989
41. Pressman MR, Benz RL, Schleifer CR, Peterson DD: Sleep disordered breathing in ESRD: Acute beneficial effects of treatment with nasal continuous positive airway pressure. Kidney Int 43: 1134-1139, 1993
42. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S: The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328: 1230-1235, 1993
43. Zoccali C, Mallamaci F, Tripepi G: Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients. J Am Soc Nephrol 13: 729-733, 2002
44. Hanly PJ, Pierratos A: Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 344: 102-107, 2001
45. Stewart GA, Gansevoort RT, Mark PB, Rooney E, McDonagh TA, Dargie HJ, Start R, Rodger C, Jardine AG: Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int 67: 217-226, 2005
46. Lorincz I, Matyus J, Zilahi Z, Kun C, Kataryi Z, Kakuk G: QT dispersion in patients with end-stage renal failure and during hemodialysis. J Am Soc Nephrol 10: 1297-1302, 1999
47. Johansson M, Gao SA, Friberg P, Annerstedt M, Carlstrom J, Ivarsson T, Jensen G, Ljungman S, Mathillas O, Nielsen FD, Strombom U: Baroreflex effectiveness index and baroreflex sensitivity predict all-cause mortality and sudden death in hypertensive patients with chronic renal failure. J Hypertens 25: 163-168, 2007
48. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M: The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 47: 219-233, 2000
49. Friedlander Y, Siscovick DS, Weinmann S, Austin MA, Psaty BM, Lemaitre RN, Arbogast P, Raghunathan TE, Cobb LA: Family history as a risk factor for primary cardiac arrest. Circulation 97: 155-160, 1998
50. Miller RF, Haley MW, Littmann L: Long QT syndrome: First and fatal events provoked by hemodialysis. Pacing Clin Electrophysiol 26: 103-104, 2003
51. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327: 1912-1918, 1992
52. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105: 1354-1359, 2002
53. Koomans HA, Blankestijn PJ, Joles JA: Sympathetic hyperactivity in chronic renal failure: A wake-up call. J Am Soc Nephrol 15: 524-537, 2004
54. Ieda M, Kanazawa H, Kimura K, Hattori F, leda Y, Taniguchi M, Lee JK, Matsumura K, Tomita Y, Miyoshi S, Shimoda K, Makino S, Sano M, Kodama I, Ogawa S, Fukuda K: Sema3a maintains normal heart rhythm through sympathetic innervation patterning. Nat Med 13: 604-612, 2007
55. Fischer R, Dechend R, Gapelyuk A, Shagdarsuren E, Gruner K, Gruner A, Gratze P, Qadri F, Wellner M, Fiebeler A, Dietz R, Luft FC, Muller DN, Schirdewan A: Angiotensin II-induced sudden arrhythmic death and electrical remodeling. Am J Physiol Heart Circ Physiol 293: H1242-H1253, 2007
56. Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, Dohi Y: Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis. A randomized study. Nephrol Dial Transplant 21: 2507-2512, 2006
57. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, Zhang Y, Xu C, Bai Y, Wang H, Chen G, Wang Z: The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13: 486-491, 2007
58. Koch M, Thomas B, Tschope W, Ritz E: Survival and predictors of death in dialysed diabetic patients. Diabetologia 36: 1113-1117, 1993
59. Zuanetti G, Maggioni AP, Keane W, Ritz E: Nephrologists neglect administration of betablockers to dialysed diabetic patients. Nephrol Dial Transplant 12: 2497-2500, 1997
60. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R: Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial. J Am Coll Cardiol 41: 1438-1444, 2003
61. Wali RK, Cooper C, Iyengar M, Beck G, Berl T, Charytan D, Chonchol M, Henrich W, Himmelfarb J, Lukas M, Cheung AK: Efficacy of carvedilol on heart failure in chronic kidney disease [Abstract]. J Am Soc Nephrol 17: 377a, 2006
62. Pun PH, Lehrich RW, Smith SR, Middleton JP: Predictors of survival following cardiac arrest in outpatient hemodialysis clinics. Clin J Am Soc Nephrol 2: 491-500, 2007
63. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Died KH, Rahn KH: Sympathetic nerve activity in end-stage renal disease. Circulation 106: 1974-1979, 2002
64. Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, Wu Y, Peixoto A, Crowley S, Desir GV: Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 115: 1275-1280, 2005
65. Blankfield RP: Pulmonary hypertension, sleep-disordered breathing, and beta blockers in heart failure patients. Sleep Breath 6: 181-187, 2002
66. Zannad F, Kessler M, Lehert P, Grunfeld JP, Thuilliez C, Leizorovicz A, Lechat P: Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of fosinopril and implications for future studies. Kidney Int 70: 1318-1324, 2006
67. van der Sman-de Beer F, Verhagen C, Rombach SM, Boorsma P, van Marten JG, Korevaar JC, van den Bogaard R, Boeschoten EW, Krediet RT, Navis GJ, Vandenbroucke JP, Dekker FW, NECOSAD Study Group: ACE I/D polymorphism is associated with mortality in a cohort study of patients starting with dialysis. Kidney Int 68: 2237-2243, 2005
68. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Alclactone Evaluation Study Investigators. N Engl J Med 341: 709-717, 1999
69. Anand K, Mooss AN, Mohiuddin SM: Aldosterone inhibition reduces the risk of sudden cardiac death in patients with heart failure. J Renin Angiotensin Aldosterone Syst 7: 15-19, 2006
70. Gross E, Rothstein M, Dombek S, Juknis HI: Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 46: 94-101, 2005
71. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP: 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110: 229-238, 2002
72. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK: Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 33: 73-81, 1999
73. Herzog CA: Don't forget the defibrillator in the dialysis unit. Nephrol Dial Transplant 19: 2959-2960, 2004
74. Lehrich RW, Pun PH, Tanenbaum ND, Smith SR, Middleton JP: Automated external defibrillators and survival from cardiac arrest in the outpatient hemodialysis clinic. J Am Soc Nephrol 18: 312-320, 2007
75. Herzog CA, Li S, Weinhandl ED, Strief JW, Collins AJ, Gilbertson DT: Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 68: 818-825, 2005
76. Dasgupta A, Montalvo J, Medendorp S, Lloyd-Jones DM, Ghossein C, Goldberger I, Passman R: Increased complication rates of cardiac rhythm management devices in ESRD patients. Am J Kidney Dis 49: 656-663, 2007
77. Robin J, Weinberg K, Tiongson J, Carnethon M, Reddy M, Ciaccio C, Quadrini M, Hsu J, Fan J, Choi P, Kadish A, Goldberger J, Passman R: Renal dialysis as a risk factor for appropriate therapies and mortality in implantable cardioverter-defibrillator recipients. Heart Rhythm 3: 1196-1201, 2006
78. Cuculich PS, Sanchez JM, Kerzner R, Greenberg SL, Sengupta J, Chen J, Faddis MN, Gleva MJ, Smith TW, Lindsay BS: Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death. Pacing Clin Electrophysiol 30: 207-213, 2007
79. Tandri H, Griffith LS, Tang T, Nasir K, Zardhoohi O, Reddy CV, Capps M, Calkins H, Donahue JK: Clinical course and long-term follow-up of patients receiving implantable cardio-verter-defibrillators. Heart Rhythm 3: 762-768, 2006
80. Isbel NM, Haluska B, Johnson DW, Beller E, Hawley C, Marwick TH: Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. Am Heart J 151: 745-753, 2006
81. Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, Pfeffer M, Simes J, Isles C, Furberg C, West M, Craven T, Curhan G: Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 16: 3748-3754, 2005
82. Ogawa K, Ikewaki K, Taniguchi I, Takatsuka H, Mori C, Sasaki H, Okazaki F, Shimizu M, Mochizuki S: Mitiglinide, a novel oral hypoglycemic agent, preserves the cardioprotective effect of ischemic preconditioning in isolated perfused rat hearts. Int Heart J 48: 337-345, 2007
83. Thisted H, Johnsen SP, Rungby J: Sulfonylureas and the risk of myocardial infarction. Metabolism 55: S16-S19, 2006
84. Bakris GL, Gaxiola E, Messerli FH, Mancia G, Erdine S, Cooper-DeHoff R, Pepine C, INVEST Investigators: Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension 44: 637-642, 2004
85. Bragg JL, Mason NA, Maroni BJ, Held PJ, Young EW: Beta-adrenergic antagonist utilization among hemodialysis patients [Abstract]. J Am Soc Nephrol 12: 321a, 2001